Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 205.74M P/E - EPS this Y 88.50% Ern Qtrly Grth -
Income -181.05M Forward P/E -1.10 EPS next Y -16.50% 50D Avg Chg 12.00%
Sales 62.39M PEG - EPS past 5Y - 200D Avg Chg -35.00%
Dividend N/A Price/Book 3.12 EPS next 5Y - 52W High Chg -65.00%
Recommedations 2.60 Quick Ratio 0.25 Shares Outstanding 5.67M 52W Low Chg 45.00%
Insider Own 22.15% ROA -57.48% Shares Float 4.07M Beta 0.50
Inst Own 51.10% ROE - Shares Shorted/Prior 462.96K/378.45K Price 2.10
Gross Margin -201.90% Profit Margin -290.20% Avg. Volume 1,890,551 Target Price 90.50
Oper. Margin -62.41% Earnings Date Oct 30 Volume 1,101,844 Change -2.33%
About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Atara Biotherapeutics, Inc. News
11/15/24 Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations
11/13/24 Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
11/12/24 Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
11/12/24 Atara Biotherapeutics: Q3 Earnings Snapshot
11/12/24 Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
11/05/24 Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
10/15/24 Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know
10/04/24 Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/30/24 After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum?
09/13/24 Redmile Group, LLC Expands Stake in Atara Biotherapeutics Inc
09/04/24 Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
09/03/24 Atara Biotherapeutics Announces $36 Million Registered Direct Offering
08/15/24 Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Just Reported Earnings, And Analysts Cut Their Target Price
08/14/24 Atara Biotherapeutics Second Quarter 2024 Earnings: Misses Expectations
08/12/24 Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
08/12/24 Atara Biotherapeutics: Q2 Earnings Snapshot
08/12/24 Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
08/07/24 Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
07/19/24 US FDA grants priority review for Pierre Fabre’s EBV+ PTLD
07/17/24 FDA priority review advances Atara’s tabelecleucel for viral infection
ATRA Chatroom

User Image Howso123 Posted - 18 hours ago

$ATRA I thought I was getting a good deal when it dropped from 14.85 to 12,this is rough.Nothing has changed as far as I can see,just have to weather the storm.

User Image EastonPrice Posted - 22 hours ago

$ATRA $AENT LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image Hudson_97 Posted - 2 days ago

$ATRA 👀

User Image murphylaw Posted - 2 days ago

$ATRA Is this the big week? Hopefully Thursday is the big pop.

User Image Howso123 Posted - 2 days ago

$ATRA Didnt expect this to tank today, thoughts?

User Image takingstock73 Posted - 3 days ago

$ATRA can someone elaborate as to the relationship between MYNZ and ATRA ? If there even is one at all Why are MYNZ bullish posts showing up here ? Could just be pumpers but curious if a more significant correlation exists.

User Image dddanielek Posted - 6 days ago

$ATRA

User Image jerzbondon Posted - 1 week ago

$ATRA I hope we will go back to $1,000

User Image LewisDaKat Posted - 1 week ago

News Article $ATRA Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference https://marketwirenews.com/news-releases/atara-biotherapeutics-to-participate-at-the-stifel-2-6293032142739455.html $ATRA

User Image DMTeddy Posted - 1 week ago

$ATRA excellent breakout, but I doubt it'll hold. Expect a reversal tomorrow to test the 10 day moving averages,~$10.85 But it looks good, expect it to be at 52 week highs by January 15th, day of FDA decision

User Image ezimon Posted - 1 week ago

$ATRA stocks do not move because of chatter.

User Image takingstock73 Posted - 1 week ago

$ATRA big movement , no chatter here , what gives ?

User Image anachartanalyst Posted - 1 week ago

$ATRA https://anachart.com/wp-content/uploads/ana_temp/1731506518_soc-img.jpg

User Image TekATL Posted - 1 week ago

$ATRA handle here sets up for 20

User Image ballyhooo Posted - 1 week ago

$ATRA Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $21

User Image ballyhooo Posted - 1 week ago

$ATRA Tab-cel BLA Accepted With Priority Review and a PDUFA Target Action Date of January 15, 2025 The BLA is supported by pivotal and supportive data covering more than 430 patients treated with tab-cel across multiple life-threatening disease.

User Image ballyhooo Posted - 1 week ago

$ATRA Investor Presentation 11/12/2024 https://d1io3yog0oux5.cloudfront.net/_0c65ce518d3d36d7c5feaf99686d1625/atarabio/db/707/6936/pdf/ATRA+Investor+Pres_Q3+2024.pdf

User Image DonCorleone77 Posted - 1 week ago

$ATRA Atara Biotherapeutics reports Q3 EPS ($2.93), consensus ($1.93) Reports Q3 revenue $40.2M, consensus $35.2M. "With the first patient now enrolled in our Phase 1 NHL trial of ATA3219, we have taken an important step in applying our proven Epstein-Barr virus platform to the significant opportunity in allogeneic CAR T," said Cokey Nguyen, Ph.D., President and Chief Executive Officer of Atara. "The first quarter of 2025 is positioned to be transformational for the company, with the potential for FDA approval of tab-cel and transition of this business to our partner Pierre Fabre, repositioning Atara as a fully focused allogeneic CAR-T company with multiple near-term data milestones for our lead program in oncology and autoimmune indications."

User Image Wiz114 Posted - 1 week ago

$ATRA what are the earings expectations

User Image shoagh12 Posted - 1 week ago

$ATRA

User Image takingstock73 Posted - 1 week ago

$ATRA looks like soon !

User Image takingstock73 Posted - 1 week ago

$ATRA when's the move to 12 ?

User Image the_real_Joker Posted - 1 week ago

$ATRA In the case of the other Car-T studies that promise breaking successes, this should resonate here and increase again at the level at the beginning of the year.

User Image Onyx99 Posted - 1 week ago

@Orlandotrader @Yuvyuv Not too long ago Sanofi had to postpone approval for Dupixent which was approved in the EU. Ironically, their initial PDUFA date was one day after $VRNA for a drug addressing COPD. $VRNA the big winner here. I bought $ATRA a few months back, 1 share only just to make sure it is on my list. I am up by 35% but still concerned over the PDUFA approval. Still not sure if/when to further invest, I will do more reading and research in the coming days and any input is appreciated!

User Image EMINENZ Posted - 1 week ago

$ATRA lol. Best stock to trade. Bought in again yesterday. Next target 12$

User Image Yuvyuv Posted - 2 weeks ago

$ATRA Nice fake drop. It will come back. Why? Because with approval they will receive $60m from the FDA plus $80m from Pierre Fabre Laboratories. That’s more than double the market cap

User Image RunFYLife Posted - 2 weeks ago

$ATRA Initiated a position here!

User Image Yuvyuv Posted - 2 weeks ago

$ATRA This stock will reach $20 before the PDUFA date; It has enough money to support operations till 2026 and with approval it will gain extra $60m, the value of its current market cap. Join the ride, you have no risk here.

User Image Orlandotrader Posted - 2 weeks ago

$ATRA Thanks for the Pullback and opportunity to add more. Ridiculous market cap. FDA decision in early January. Moon Shot Opportunity.

User Image PenkeTrading Posted - 2 weeks ago

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Atara Biotherapeutics Inc. Is that bullish or bearish? $ATRA #RsiOverbought #NASDAQ

Analyst Ratings
HC Wainwright & Co. Neutral Aug 21, 24
Mizuho Outperform Aug 16, 24
Canaccord Genuity Buy Aug 13, 24
Goldman Sachs Sell Jul 17, 24
HC Wainwright & Co. Neutral May 22, 24
Stifel Hold Apr 1, 24
Goldman Sachs Sell Nov 10, 23
Evercore ISI Group In-Line Nov 9, 23
HC Wainwright & Co. Neutral Nov 9, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Gallagher Carol Giltner Director Director Nov 13 Buy 0.27 270,000 72,900 459,418 11/15/23
HEIDEN WILLIAM K Director Director Nov 10 Buy 0.2533 100,000 25,330 209,000 11/14/23
DOBMEIER ERIC Director Director Nov 10 Buy 0.2268 446,825 101,340 563,325 11/14/23
Hyllengren Eric J SVP, CFO SVP, CFO Aug 16 Sell 1.65 8,186 13,507 217,956 08/18/23
Murugan Amar EVP, Chief Legal Off.. EVP, Chief Legal Officer Aug 16 Sell 1.65 8,672 14,309 265,391 08/18/23
Touchon Pascal President and CEO President and CEO Aug 16 Sell 1.65 30,766 50,764 675,905 08/18/23
Nguyen AnhCo EVP, Chief Sci. & Te.. EVP, Chief Sci. & Tech Officer Aug 16 Sell 1.65 15,126 24,958 285,999 08/18/23
Joshi Manher EVP, Chief Medical O.. EVP, Chief Medical Officer Aug 16 Sell 1.65 6,975 11,509 183,571 08/18/23
Henrich Jill EVP, Global Head RA.. EVP, Global Head RA & Quality Aug 16 Sell 1.65 3,346 5,521 107,691 08/18/23
Murugan Amar EVP, Chief Legal Off.. EVP, Chief Legal Officer May 16 Sell 2.04 8,389 17,114 270,945 05/18/23
Banard Charlene A. EVP, Chief Technical.. EVP, Chief Technical Officer May 16 Sell 2.037 19,040 38,784 276,010 05/18/23
Touchon Pascal President and CEO President and CEO May 16 Sell 2.037 29,766 60,633 720,962 05/18/23
Hyllengren Eric J SVP, CFO SVP, CFO May 16 Sell 2.04 7,918 16,153 226,142 05/18/23
Touchon Pascal President and CEO President and CEO Mar 02 Sell 3.627 15,679 56,868 750,728 03/06/23
Murugan Amar SVP, GC & Secretary SVP, GC & Secretary Mar 02 Sell 3.627 4,221 15,310 279,334 03/06/23
Koppikar Utpal Chief Financial Offi.. Chief Financial Officer Mar 02 Sell 3.627 6,871 24,921 181,978 03/06/23
Dupont Jakob EVP, Head of R&D EVP, Head of R&D Mar 02 Sell 3.627 5,074 18,403 290,794 03/06/23
Koppikar Utpal Chief Financial Offi.. Chief Financial Officer Feb 07 Sell 5.46 2,485 13,568 188,849 02/09/23
Dupont Jakob EVP, Head of R&D EVP, Head of R&D Nov 16 Sell 4.49 4,342 19,496 154,540 11/18/22
Touchon Pascal President and CEO President and CEO Nov 16 Sell 4.49 15,591 70,004 441,696 11/18/22
Murugan Amar SVP, GC & Secretary SVP, GC & Secretary Nov 16 Sell 4.49 3,612 16,218 127,586 11/18/22
Koppikar Utpal Chief Financial Offi.. Chief Financial Officer Nov 16 Sell 4.49 6,255 28,085 191,334 11/18/22
Touchon Pascal President and CEO President and CEO Aug 16 Sell 5.035 14,806 74,548 457,287 08/18/22
Dupont Jakob EVP, Head of R&D EVP, Head of R&D Aug 16 Sell 5.034 4,124 20,760 158,882 08/18/22
Murugan Amar SVP, GC & Secretary SVP, GC & Secretary Aug 16 Sell 5.03 3,430 17,253 131,198 08/18/22
Koppikar Utpal Chief Financial Offi.. Chief Financial Officer Aug 16 Sell 5.035 5,940 29,908 197,589 08/18/22
Touchon Pascal President and CEO President and CEO Jun 27 Sell 7.20 14,220 102,384 472,093 06/29/22
Murugan Amar SVP, GC & Secretary SVP, GC & Secretary May 17 Sell 5.32 3,223 17,146 133,735 05/19/22
Koppikar Utpal Chief Financial Offi.. Chief Financial Officer May 17 Sell 5.32 5,582 29,696 207,592 05/19/22
Dupont Jakob EVP, Head of R&D EVP, Head of R&D May 17 Sell 5.318 3,873 20,597 163,006 05/19/22
Touchon Pascal President and CEO President and CEO May 17 Sell 5.316 13,913 73,962 486,313 05/19/22
Koppikar Utpal Chief Financial Offi.. Chief Financial Officer Mar 01 Sell 9.86 3,763 37,103 213,174 03/03/22
Dupont Jakob EVP, Head of R&D EVP, Head of R&D Mar 01 Sell 9.86 2,221 21,899 166,879 03/03/22
Touchon Pascal President and CEO President and CEO Mar 01 Sell 9.86 8,828 87,044 500,226 03/03/22
Murugan Amar SVP, GC & Secretary SVP, GC & Secretary Mar 01 Sell 9.86 2,577 25,409 136,958 03/03/22
Dupont Jakob EVP, Head of R&D EVP, Head of R&D Feb 10 Option 9.58 5,000 47,900 95,594 02/14/22
Dupont Jakob EVP, Head of R&D EVP, Head of R&D Feb 10 Sell 16 5,000 80,000 90,594 02/14/22
Newell Joe Chief Operations Off.. Chief Operations Officer Dec 18 Option 12.15 3,500 42,525 120,055 12/18/20
Newell Joe Chief Operations Off.. Chief Operations Officer Dec 18 Sell 23.11 7,000 161,770 113,055 12/18/20